.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,318,800

« Back to Dashboard

Claims for Patent: 8,318,800

Title:Solid pharmaceutical compositions containing benzofuran derivatives
Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
Inventor(s): Abramovici; Bernard (Juvignac, FR), Gautier; Jean-Claude (Clapiers, FR), Gromenil; Jean-Claude (Montbazin, FR), Marrier; Jean-Marie (Lattes, FR)
Assignee: Sanofi (Paris, FR)
Application Number:11/955,565
Patent Claims: 1. A solid pharmaceutical composition for oral administration comprising dronedarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients wherein the nonionic hydrophilic surfactant is present in a proportion of from 1% to 50% by weight of the active principle in base form.

2. The pharmaceutical composition according to claim 1, wherein the active principle is dronedarone hydrochloride.

3. The pharmaceutical composition according to claim 1 wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamers, polyethoxylated castor oils, and polyethylene hydroxystearates.

4. The pharmaceutical composition according to claim 3, wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, and polyethylene hydroxystearate 660.

5. The pharmaceutical composition according to claim 4 wherein the nonionic hydrophilic surfactant is poloxamer 407.

6. The pharmaceutical composition according to claim 1, which is in a tablet or a gelatin capsule form, wherein the nonionic hydrophilic surfactant is present in a proportion of from 1% to 20% by weight of the active principle in base form.

7. The pharmaceutical composition according to claim 6, which is in a tablet or a gelatin capsule form, wherein the nonionic hydrophilic surfactant is present in a proportion of from 5% to 15% by weight of the active principle in base form.

8. The pharmaceutical composition according to claim 1 containing from 50 to 500 mg of active principle.

9. The pharmaceutical composition according to claim 8, which is in a tablet or a gelatin capsule form, containing from 200 to 400 mg of active principle.

10. The pharmaceutical composition according to claim 9, which is in a tablet or a gelatin capsule form, containing from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

11. The pharmaceutical composition according to claim 10 wherein the nonionic hydrophilic surfactant is poloxamer 407.

12. The pharmaceutical composition according to claim 1 comprising one or more pharmaceutical excipients selected from the group consisting of a binder, a flow agent, a vinylpyrrolidone polymer or copolymer, a diluent, a starch and a lubricant.

13. The pharmaceutical composition according to claim 12, wherein the one or more pharmaceutical excipients is selected from the group consisting of methylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose, a macrogol, colloidal silica, polyvinylpyrrolidone, lactose, mannitol, wheat starch, corn starch, magnesium stearate, and sodium stearyl fumarate.

14. A solid pharmaceutical composition in tablet form for oral administration consisting essentially of dronedarone or a pharmaceutically acceptable salt thereof, as an active principle; a pharmaceutically acceptable nonionic hydrophilic surfactant, wherein said nonionic hydrophilic surfactant is a poloxamer; and one or more pharmaceutical excipients; said nonionic hydrophilic surfactant being present in a proportion of from 5% to 15% by weight of the active principle in base form.

15. The pharmaceutical composition according to claim 14 wherein the one or more pharmaceutical excipients are selected from the group consisting of a binder, a flow agent, a vinylpyrrolidone polymer or copolymer, a diluent, a starch and a lubricant.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc